Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GoodRx

Why “GoodRx” is No Longer Enough: The 2026 Drug Reclassifications You Weren’t Told About

For years, many of us treated GoodRx like a secret weapon. If a prescription was too expensive through insurance, we’d just pull up a coupon...

Pharmacy Discount Programs Are Shrinking at National Chains

Pharmacy Discount Programs Are Shrinking at National Chains

If you’ve relied on pharmacy discount cards like GoodRx, SingleCare, or Optum Perks to save on prescriptions, you likely noticed a shift in your January...

My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs

My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs

Even when Americans have health insurance, they can have a hard time affording the drugs they’ve been prescribed.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Prescription Discount Cards Are Being Restructured by Major Retailers

Prescription discount cards have long helped retirees reduce out-of-pocket medication costs. These cards, offered by companies like GoodRx, SingleCare, and Optum Perks, typically provide savings...

GoodRx Stock Could Get a Major Trump Boost. Should You Buy It Here?

With a potential TrumpRx partnership, should investors buy GDRX stock now?

GoodRx CEO says successful leadership is about more than staying calm through chaos: It’s about bosses reclaiming control

The post‑pandemic pendulum swung too far in employees’ favor, warns GoodRx’s Wendy Barnes—and business leaders need to build resilient teams that execute under pressure.

Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch

Prescription savings platform GoodRx Holdings Inc. (NASDAQ:GDRX) is reportedly joining the so-called TrumpRx website, signaling an initiative expansion beyond pharmaceutical manufacturers' direct discount programs.

inkl

Read news from The Economist, FT, and more,
with one subscription

A new era of access demands smarter design for direct-to-consumer drug pricing

A new era of access demands smarter design for direct-to-consumer drug pricing

A Fortune Most Powerful Women member, Barnes believes there are three essential elements for effective DTC models.

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

What's Going On With Hims & Hers Shares Today?

What's Going On With Hims & Hers Shares Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after GoodRx Inc. (NASDAQ:GDRX) announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, Ozempic and Wegovy.

Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk

Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes.

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx Holdings Inc (NASDAQ:GDRX) shares are pulling back Tuesday morning, as investors potentially take profits following Monday’s surge. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk to expand access to popular GLP-1 medications.

How GoodRx CEO Wendy Barnes is trying to halve the cost of GLP-1 obesity drugs

How GoodRx CEO Wendy Barnes is trying to halve the cost of GLP-1 obesity drugs

Also: All the news and watercooler chat from Fortune.

GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access

GoodRx Holdings Inc. (NASDAQ:GDRX) shares jumped 5.08% in after-hours trading on Monday, following the announcement of a collaboration with Novo Nordisk A/S (NYSE:NVO) to offer discounted GLP-1 medications at fixed pricing nationwide.

Get all your
news in one place.

100’s of premium titles.
One news app.

GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

The previous out-of-pocket price was nearly $1,000.

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective immediately.

Woman donates plasma for ‘extra money.’ Then she issues a warning about the unexpected side effect she’s experiencing

Donating plasma is one of the lesser known ways people can make some extra money without doing much. You just show up at a donation center, endure the prick of a needle, and collect some cash at the end.

Get all your
news in one place.

100’s of premium titles.
One news app.

If you have Medicare, here’s what you’ll pay for health care in 2025

The most significant Medicare change for 2025 will be the new $2,000 cap for prescription drugs.

How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals

GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024.

Charter Names Simon Cassels SVP, Chief Creative Officer

Cassels’ award-winning accomplishments include Apple’s “Shot on iPhone” campaign

Take a Mid-Year Review of Your Health Insurance Coverage

Whether it's monitoring your deductible or using a health savings account, here are the best ways to maximize use of your health insurance coverage

3 Top Stocks Under $10 to Buy Instead of GameStop

Meme stocks such as GME and AMC have risen substantially this month. However, due to their weak fundamentals, these companies are high-risk investments.

Sempre Health's innovative approach improves medication adherence and lowers costs

Initiatives like GoodRx and Sempre Health are working towards transparency and affordability in the drug supply chain to improve medication adherence. Blue...

A popular asthma inhaler is leaving pharmacy shelves. Here's what you need to know

Flovent — a common asthma inhaler — will be discontinued in 2024. There will be a generic version available, but the change could make it hard for some patients to get their medication.

People

166,546 stories

David Lipschutz

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Bank of America

Medicare Advantage

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Social Security

Prescription Drug

Places

340,198 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play